THERMO FISHER SCIENTIFIC

(TMO)
  Report
Real-time Estimate Cboe BZX  -  05/23 03:07:40 pm EDT
552.64 USD   -0.45%
05/19THERMO FISHER SCIENTIFIC INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/19Thermo Fisher Scientific Maintains Quarterly Dividend at $0.30 a Share, Payable July 15 to Shareholders as of June 15
MT
05/19Thermo Fisher Scientific Declares Quarterly Dividend
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

THERMO FISHER SCIENTIFIC INC. : Regulation FD Disclosure (form 8-K)

01/21/2022 | 06:33am EDT

Item 7.01 Regulation FD Disclosure.

On January 21, 2022, Thermo Fisher Scientific Inc. (the "Company") notified the holders of its $350,000,000 aggregate principal amount of 3.650% Senior Notes due 2025 (the "Notes") that it will redeem all of the Notes on February 7, 2022 (the "Redemption Date"). The Notes will be redeemed at a redemption price equal to the greater of (i) 100% of the principal amount of the Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of the Notes to be redeemed discounted to the Redemption Date on a semi-annual basis at a comparable treasury rate plus 25 basis points, plus accrued and unpaid interest on the Notes to be redeemed, if any, to, but excluding, the Redemption Date.

The Company intends to fund the aggregate redemption price using cash on hand.

The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company's statements about its intended source of funds for the redemption. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to general economic conditions and related uncertainties; the effect of changes in governmental regulations; and any natural disaster, public health crisis or other catastrophic event. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the "Investors" section of the Company's website under the heading "SEC Filings," and other documents the Company files with the SEC. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this Current Report on Form 8-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about THERMO FISHER SCIENTIFIC
05/19THERMO FISHER SCIENTIFIC INC. : Submission of Matters to a Vote of Security Holders (form ..
AQ
05/19Thermo Fisher Scientific Maintains Quarterly Dividend at $0.30 a Share, Payable July 15..
MT
05/19Thermo Fisher Scientific Declares Quarterly Dividend
BU
05/19Thermo Fisher Scientific Inc. Declares Quarterly Dividend, Payable on July 15, 2022
CI
05/19Thermo Fisher Scientific and LabShares Newton Partner to Support Emerging Boston Biotec..
CI
05/18TRANSCRIPT : Thermo Fisher Scientific Inc. - Analyst/Investor Day
CI
05/11TRANSCRIPT : Thermo Fisher Scientific Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/11IonPath, Inc. announced that it has received funding from Thermo Fisher Scientific Inc.
CI
05/10Thermo Fisher Scientific Introduces QualTrak Biopharma qPCR Solutions to Streamline Bio..
CI
05/06THERMO FISHER SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condit..
AQ
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 42 470 M - -
Net income 2022 6 946 M - -
Net Debt 2022 25 212 M - -
P/E ratio 2022 31,8x
Yield 2022 0,21%
Capitalization 217 B 217 B -
EV / Sales 2022 5,71x
EV / Sales 2023 5,42x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 555,15 $
Average target price 666,21 $
Spread / Average Target 20,0%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-16.80%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644
BOSTON SCIENTIFIC CORPORATION-7.67%56 068